Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by ...

The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

At the recent Eudēmonia Summit, Dr. Sara Gottfried explained why understanding the root cause of chronic illness is more ...

H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on BPMC stock, giving a Buy rating today. Andrew Fein’s rating ...

We recently published a list of 10 Best Multibagger Stocks To Buy Heading into 2025. In this article, we are going to take a ...

Monjuvi is available under an accelerated approval to treat adults with relapsed or refractory diffuse large B-cell lymphoma.